By Coastal Carolina News Staff Writer
HEALTH NEWS: An experimental Alzheimer’s drug developed by Biogen is showing encouraging results, with researchers reporting significantly slower cognitive decline among patients with early-stage disease.
In a Phase 2 clinical trial, patients receiving the lowest dose of diranersen every 24 weeks experienced 54% less decline on a key measure of memory and cognitive function over two years compared with those who received a placebo.
The findings are notable because the drug targets tau, a protein strongly linked to Alzheimer’s progression. Most recently approved Alzheimer’s treatments focus on amyloid plaques, making diranersen one of the first therapies to show potential benefits from targeting a different disease pathway.
Researchers also reported slower overall clinical decline and improvements across multiple measures of cognition and daily functioning. The drug was generally well tolerated, with no new safety concerns identified during the study’s two-year follow-up.
While the treatment remains experimental, Biogen plans to advance diranersen into larger Phase 3 trials.
If future studies confirm the results, the drug could become a significant new tool in treating a disease that currently has no cure.
Health Disclosure: This article is for informational purposes only and should not be considered medical advice. The treatment discussed remains experimental and has not been approved for general use.
© 2026 CoastalCarolinaNews.com. All rights reserved.

Be the first to comment